ArticleJournal of cachexia, sarcopenia and muscle2025
Motoric Cognitive Risk Syndrome Associated With Risk of Frailty and Likelihood of Reversion in Older Adults.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Motoric Cognitive Risk Syndrome Associated With Risk of Frailty and Likelihood of Reversion in Older Adults.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMotoric cognitive risk syndrome (MCR), a predementia condition, is reported to be associated with frailty. However, the associations of MCR with frailty risk and its reversibility remain unclear.
methodsA longitudinal study was conducted of 10 809 older adults from the Health and Retirement Study in the United States. Frailty was assessed by the frailty index and reversibility was measured by transitions from frailty at baseline to non-frailty during follow-up. MCR was defined as the presence of both subjective cognitive complaints and slow gait speed in individuals without dementia or mobility disability. Multistate Markov models were performed to evaluate the effects of MCR on transitions among non-frailty, frailty and death. Cox regression models were used to estimate MCR associated with the risk of frailty and the likelihood of reversion.
resultsAmong 10 809 participants with a median age of 71 (interquartile range: 67-71) years and 6462 (57.93%) females, a total of 105 372 person-years (9.75 years in average) were followed up. The prevalence of MCR at baseline in non-frail and frail participants was 3.12% and 18.56%, respectively. Compared with non-MCR, MCR increased the probability of transitioning from non-frailty to frailty by 46% (HR = 1.46, 95% CI: 1.27-1.67) and decreased the probability of transitioning from frailty to non-frailty by 36% (HR = 0.64, 95% CI: 0.52-0.77). Compared with normal function, subjective cognitive complaints only, slow gait speed only and MCR increased the probability of transitioning from non-frailty to frailty by 43% (HR = 1.43, 95% CI: 1.33-1.53), 14% (HR = 1.14, 95% CI: 1.00-1.30) and 69% (HR = 1.69, 95% CI: 1.47-1.96) and decreased the probability of transitioning from frailty to non-frailty by 18% (HR = 0.82, 95% CI: 0.74-0.92), 27% (HR = 0.73, 95% CI: 0.60-0.88) and 45% (HR = 0.55, 95% CI: 0.45-0.67), respectively. As shown in the prospective analyses, MCR and its single component were associated with increased frailty risk and decreased likelihood of reversion.
conclusionsMCR is associated with an increased risk of frailty, accelerated transition from non-frailty to frailty and a decreased likelihood of reversion from frailty. MCR emerges as a promising risk stratification factor for frailty, highlighting the need for increased focus on individuals with MCR, particularly within the pre-frail population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.